<DOC>
	<DOCNO>NCT01645202</DOCNO>
	<brief_summary>A randomize control multicenter study compare acute hemodynamic performance Edwards Sapien XT Medtronic CoreValve transcatheter heart valves high risk patient severe symptomatic aortic stenosis .</brief_summary>
	<brief_title>A Comparison Transcatheter Heart Valves High Risk Patients With Severe Aortic Stenosis : The CHOICE Trial</brief_title>
	<detailed_description>Study design : randomize open-label multicenter Primary endpoint : 'Device success ' recently define VARC 'technical ' composite endpoint include : 1 . Successful vascular access , delivery deployment device successful retrieval delivery system , 2 . Correct position device proper anatomical location , 3 . Intended performance prosthetic heart valve ( aortic valve area &gt; 1.2 cm2 mean aortic valve gradient &lt; 20 mmHg peak velocity &lt; 3 m/s , without moderate severe prosthetic valve AR ) 4 . Only one valve implant proper anatomical location . Secondary endpoint : - 30-day-combined safety endpoint combine endpoint define VARC : 1 . All cause mortality , 2 . Major stroke , 3 . Life threaten ( disable ) bleeding , 4 . Acute kidney injury-Stage 3 ( include renal replacement therapy ) , 5 . Periprocedural myocardial infarction , 6 . Major vascular complication 7 . Repeat procedure valve-related dysfunction ( surgical interventional therapy ) . * - Combined efficacy endpoint 1 year composite endpoint define VARC : 1 . All cause mortality 30 day one year , 2 . Failure current therapy aortic stenosis , require hospitalization symptom valve-related cardiac decompensation 3 . Prosthetic heart valve dysfunction ( aortic valve area &lt; 1.2 cm2 mean aortic valve gradient &gt; 20 mmHg peak velocity &gt; 3 m/s moderate severe prosthetic valve AR ) . * - Cardiovascular mortality define VARC 1 month , 6 12 month . * - Major adverse cardiovascular cerebrovascular event ( MACCE ) : myocardial infarction , cardiac vascular surgery stroke 30 day , 6 &amp; 12 month . - Rehospitalization heart failure 12 month - Quality life ( assessed Euro5Qual-questionnaire ) 12 month - NYHA-class improvement 30 day , 6 12 month - Vascular complication define VARC 30 day . - Post-procedural pacemaker implantation 1 month - Major minor Bleeding 30 day define VARC .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Severe aortic valve stenosis define aortic valve area ( AVA ) ≤ 1cm2 0.6 cm2/m2 2 . Presence clinical symptom define New York Heart Association ( NYHA ) functional class ≥ 2 3 . Age &gt; 75 year and/or Logistic EuroSCORE ≥ 20 % and/or STS risk score ≥ 10 % and/or contraindication conventional surgical aortic valve replacement ( porcelain aorta , previous chest radiation , chest deformation ) 4 . Native aortic valve annulus measure 2025 mm 5 . Patients must suitable transfemoral vascular access 6 . The patient signing write informed consent prior intervention 1 . Life expectancy &lt; 12 month due comorbid condition 2 . Native aortic valve annulus &lt; 20 mm &gt; 25 mm ( could amend valve sizes transfemoral approach become available prosthesis study period ) 3 . Preexisting aortic bioprosthesis 4 . Cardiogenic shock hemodynamic instability 5 . History , active endocarditis 6 . Contraindications transfemoral access 7 . Active peptic ulcer upper gastrointestinal bleeding within prior 3 month . 8 . Hypersensitivity contraindication aspirin , heparin clopidogrel 9 . Active infection require antibiotic treatment 10 . An elective surgical procedure plan would necessitate interruption thienopyridines first 3 month postenrolment 11 . Patients actively participate another drug device investigational study yet complete primary endpoint followup period</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Aortic stenosis</keyword>
	<keyword>TAVI</keyword>
	<keyword>Device success</keyword>
	<keyword>Aortic regurgitation</keyword>
</DOC>